Retraction
The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway
Paper Information
Record ID:
53537
Author(s):
Journal:
Publication Date:
March 02, 2018
Retraction Date:
February 09, 2023
(2.8 years years ago)
Subjects:
Institutions:
- Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, 621 Gangwan RD, Huangpu District, Guangzhou, 510700, Guangdong, China
- Minimally Invasive Technique and Product Translational Center, Guangzhou Medical University, Guangzhou, Guangdong, China
- Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
- Department of Urology, The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Country:
🇨🇳 ChinaArticle Type:
Publisher:
Springer - Biomed Central (BMC)
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1186/s13578-023-00976-xAdditional Notes:
See also: https://pubpeer.com/publications/6129191836DFC2B9A940B0CC0A0F84
Citations (18)
18
Total Citations4
Post-Retraction(22.2%)
14
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
3
Within 1 year
0
After 2+ years
575
Days since retraction (latest)
Molecular biology and epigenetic modifications definition
Fatemeh Khatami, Razman Arabzadeh Bahri, Hossein Sharifkazemi et al. (6 authors)
Elsevier eBooks
Published: Sep 2024
575 days after retraction
Non-coding RNAs as therapeutic targets in cancer and its clinical application
Xuejiao Leng, Mengyuan Zhang, Yujing Xu et al. (12 authors)
Journal of Pharmaceutical Analysis
Open Access
Published: Feb 2024
14 citations
14 citations
364 days after retraction
circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape
Li-Feng Dong, Fangfang Chen, Yang-Fan Fan et al. (5 authors)
Journal for ImmunoTherapy of Cancer
Open Access
Published: Jun 2023
12 citations
12 citations
112 days after retraction
CDKN2B-AS1 as a novel therapeutic target in cancer: Mechanism and clinical perspective
Ahmed Hjazi, Eishah Ghaffar, Waqas Asghar et al. (11 authors)
Biochemical Pharmacology
Published: May 2023
23 citations
23 citations
109 days after retraction
The roles of long non‑coding RNAs in renal cell carcinoma (Review)
ZHENGMING SU, Jian Ao, Fengjin Zhao et al. (6 authors)
Molecular and Clinical Oncology
Open Access
Published: Nov 2022
3 citations
3 citations
73 days before retraction
CCL18 Knockdown Suppresses Cell Growth and Migration in Thyroid Cancer
Caixia Sun, Ping Wang, Tiantian Gao et al. (4 authors)
Journal of Healthcare Engineering
Open Access
Published: Jan 2022
5 citations
5 citations
380 days before retraction
miR-622 Induces Breast Cancer Cell MCF-7 Proliferation, Migration, and Invasion by Directly Negatively Targeting EYA1
Pan Tang, Yanyan Shen, Jihui Yang et al. (7 authors)
Journal of Nanomaterials
Open Access
Published: Jan 2022
5 citations
5 citations
404 days before retraction
The expression and function of miR-622 in a variety of tumors
Juan Lü, Zhongyang Xie, Zhaoying Xiao et al. (4 authors)
Biomedicine & Pharmacotherapy
Open Access
Published: Dec 2021
11 citations
11 citations
416 days before retraction
MiR‐622 acts as a tumor suppressor to induce cell apoptosis and inhibit metastasis in human prostate cancer
Niloufar Targhazeh, Bahman Yousefi, Samira Asghari et al. (6 authors)
Andrologia
Open Access
Published: Jul 2021
11 citations
11 citations
583 days before retraction
A multi-cellular molecular signaling and functional network map of C–C motif chemokine ligand 18 (CCL18): a chemokine with immunosuppressive and pro-tumor functions
Anjana Aravind, Akhina Palollathil, Rex Devasahayam Arokia Balaya et al. (9 authors)
Journal of Cell Communication and Signaling
Open Access
Published: Jul 2021
19 citations
19 citations
588 days before retraction
Sevoflurane inhibits malignant progression of colorectal cancer via hsa_circ_0000231-mediated miR-622
Jingpeng Wang, Shuyuan Li, Gaofeng Zhang et al. (4 authors)
Journal of Biological Research - Thessaloniki
Open Access
Published: Jun 2021
9 citations
9 citations
591 days before retraction
The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment
Ana Patrícia Cardoso, Marta L. Pinto, Flávia Castro et al. (9 authors)
Cytokine & Growth Factor Reviews
Open Access
Published: Apr 2021
49 citations
49 citations
679 days before retraction
A Review of Recent Research on the Role of MicroRNAs in Renal Cancer
Longfei Yang, Xiaofeng Zou, Junrong Zou et al. (4 authors)
Medical Science Monitor
Open Access
Published: Feb 2021
26 citations
26 citations
715 days before retraction
CircUBXN7 mitigates H/R-induced cell apoptosis and inflammatory response through the miR-622-MCL1 axis.
Sheng Wang, Zhaoyun Cheng, Xianjie Chen et al. (6 authors)
American Journal of Translational Research
Published: Jan 2021
21 citations
21 citations
769 days before retraction
CCL18 in the Progression of Cancer
Jan Korbecki, Mateusz Olbromski, Piotr Dzięgiel
International Journal of Molecular Sciences
Open Access
Published: Oct 2020
81 citations
81 citations
836 days before retraction
miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase
Francesca Maria Orlandella, Raffaela Mariarosaria Mariniello, Peppino Mirabelli et al. (14 authors)
British Journal of Cancer
Open Access
Published: May 2020
30 citations
30 citations
998 days before retraction
<p>Molecular subtype classification of papillary renal cell cancer using miRNA expression</p>
Changwen Yu, Danjing Dai, Juan Xie
OncoTargets and Therapy
Open Access
Published: Mar 2019
2 citations
2 citations
1441 days before retraction
Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy
Meng Du, Zhiyi Chen, Yuhao Chen et al. (4 authors)
Current Drug Targets
Published: Dec 2018
21 citations
21 citations
1513 days before retraction
Quick Stats
Total Citations:
18
Years Since Retraction:
2.8 years
Open Access:
Yes
Last Checked:
Jul 24, 2025